RT Journal Article
SR Electronic
T1 Multi-center evaluation of baseline neutrophil:lymphocyte (NLR) ratio as an independent predictor of mortality and clinical risk stratifier in Idiopathic Pulmonary Fibrosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.29.22274470
DO 10.1101/2022.04.29.22274470
A1 Theresia A Mikolasch
A1 Peter M. George
A1 Jagdeep Sahota
A1 Thomas Nancarrow
A1 Shaney L Barratt
A1 Felix A. Woodhead
A1 Vasilis Kouranos
A1 Victoria S A Cope
A1 Andrew W Creamer
A1 Silan Fidan
A1 Balaji Ganeshan
A1 Luke Hoy
A1 John A Mackintosh
A1 Robert Shortman
A1 Anna Duckworth
A1 Janet Fallon
A1 Helen Garthwaite
A1 Melissa Heightman
A1 Huzaifa I Adamali
A1 Sarah Lines
A1 Thida Win
A1 Rebecca Wollerton
A1 Elisabetta A Renzoni
A1 Matthew Steward
A1 Athol U. Wells
A1 Michael Gibbons
A1 Ashley M Groves
A1 Bibek Gooptu
A1 Chris J. Scotton
A1 Joanna C. Porter
YR 2022
UL http://medrxiv.org/content/early/2022/04/29/2022.04.29.22274470.abstract
AB Background Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disorder with a variable disease trajectory. The aim of this study was to assess the potential of neutrophil-to-lymphocyte ratio (NLR) to predict outcomes for people with IPF.Method We adopted a two-stage discovery and validation design using patients from the UCL partners (UCLp) cohort. For the discovery analysis, we included 71 patients from UCLH. In the validation analysis, we included 928 people with IPF, using real-life data from UCLH and 5 other UK centres. Data were collected from patients presenting over a 13-year period with a mean follow up time of 3.7 years.Findings In the discovery analysis, we showed that values of NLR (<2.9 vs >/=2.9) were associated with increased risk of mortality (HR 2.04, 95% CI 1.09-3.81; p=0.025). In the validation cohort we confirmed this association of high NLR with mortality (HR 1.65, 95% CI 1.39-1.95; p<0·0001) and showed incorporation of baseline NLR in a modified GAP-stage/index (GAP/index)-plus improved predictive abilityInterpretation We have identified NLR as a widely available test that significantly correlates with lung function, can predict outcomes in IPF and refines clinical GAP-staging. NLR may help ILD specialist centres prioritise at risk patients in a timely way, even in the absence of lung function.Competing Interest StatementPMG reports consultant fees from Boehringer Ingelheim (BI) and AstraZeneca (AZ) and lecturing honoraria from BI, Roche and Cipla. ER reports lecturing fees from BI and Mundipharma. JCP reports consulting fees from Carrick therapeutics, AZ and lecturing honaria from The Limbic.Funding StatementThis work was supported by Breathing Matters, and undertaken at Exeter, Leicester, Imperial and UCLH/UCL BRCs who receive a proportion of funding from the Department of Health`s NIHR Biomedical Research Centres funding scheme. TAM held an independent studentship from GSK. TN held a joint studentship from the Cystic Fibrosis Trust and the British Lung Foundation (SS19/06) JCP had an MRC New Investigator Award (MR/K004158/1). AD was supported in part by grant MR/N0137941/1 for the GW4 BIOMED MRC DTP, awarded to the Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research Council (MRC)/UKRI. CJS was supported by an MRC grant (MR/V002538/1). RW was supported by an NIHR Academic Clinical Fellowship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ETHICAL APPROVALS AND FUNDING Ethical approval (and any ensuing amendments) was granted by the London - Harrow Research Ethics Committee. (REC reference: 18/LO/0937). Site specific and local R&D approvals were granted by each participating hospital site. The study was sponsored by University College London (UCL).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors